Search

Displaying results 5131 - 5140 of 10000 in total
  1. Drug

    Cariporide

    go.drugbank.com/drugs/DB06468
    Experimental

  2. Drug

    Candida albicans

    go.drugbank.com/drugs/DB10429
    ApprovedInvestigational

    Candida albicans is used in allergenic testing.

  3. Drug

    Saccharomyces cerevisiae

    go.drugbank.com/drugs/DB10447
    Approved

    Saccharomyces cerevisiae is used in allergenic testing.

    Mixtures: B Complex
  4. Drug

    Oxyphenbutazone

    go.drugbank.com/drugs/DB03585
    ApprovedWithdrawn

    Oxyphenbutazone was withdrawn from the Canadian market in March 1985 due to concerns regarding bone marrow suppression.

  5. Drug

    Ligelizumab

    go.drugbank.com/drugs/DB11856
    Investigational

    Similar in mechanism to [omalizumab], another IgE-directed monoclonal antibody, ligelizumab has a distinct binding epitope as compared to its peer (with a small degree of overlap) which appears to confer … efficacy anti-IgE antibody therapy in the treatment of CSU has been previously established with omalizumab.

  6. Drug

    Cedar oil

    go.drugbank.com/drugs/DB10917
    Approved

    Cedar oil (Juniperus virginiana) allergenic extract is used in allergenic testing.

  7. Drug

    Zeaxanthin

    go.drugbank.com/drugs/DB11176
    ApprovedInvestigational

    Zeaxanthin is a most common carotenoid alcohols found in nature that is involved in the xanthophyll cycle. … As a coexistent isomer of lutein, zeaxanthin is synthesized in plants and some micro-organisms.

  8. Drug

    Sufugolix

    go.drugbank.com/drugs/DB06494
    Experimental

  9. Drug

    Altropane

    go.drugbank.com/drugs/DB04947
    Investigational

    Boston Life Sciences (BLS) is developing Altropane as a potential radio-imaging agent to be used with single photon emission tomography (SPECT), for the early diagnosis of Parkinson's disease (PD) and attention deficit hyperactivity diso...

  10. Drug

    XL019

    go.drugbank.com/drugs/DB05243
    Investigational

    An IND for XL019 was filed by Exelixis in May 2007.